查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1438129

到 2030 年泌尿道治療市場預測：按類型、治療類型、診斷、最終用戶和地區進行的全球分析

Uropathy Treatment Market Forecasts to 2030 - Global Analysis By Type (Obstructive Uropathy, Functional Uropathy, Inflammatory Uropathy, Congenital Uropathy and Urological Cancers), Treatment Type, Diagnosis, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球泌尿道疾病治療市場規模為 44 億美元，預計到 2030 年將達到 66 億美元，預測期內複合年成長率為 6.0%。

泌尿道疾病是指影響泌尿道的多種疾病，包括腎臟、輸尿管、膀胱和尿道。泌尿道疾病的治療取決於根本原因和嚴重程度。透過 3D 前列腺 MRI 等先進影像技術進行早期診斷可以及時進行干預。個人化醫療根據個人的遺傳和分子特徵量身定做治療計劃，為更有效、更有針對性的治療鋪平道路。

根據發表在《泌尿學進展》雜誌上的一項研究，腎結石影響著世界上大約15% 的人口，儘管它影響所有年齡層的人，但在20 至49 歲之間，男性比女性更常見。泌尿系統疾病頻繁發生且呈上升趨勢。

泌尿系統疾病發生率增加

隨著尿道感染、腎結石和攝護腺疾病的盛行率持續上升，對有效和創新治療方法的需求不斷成長。患者數量的快速增加不僅凸顯了對先進治療解決方案的迫切需求，也推動了泌尿系統治療領域的研發力度。因此，在意識和教育提高的推動下，人們對泌尿系統健康的興趣日益濃厚，將進一步加速市場擴大，增加對診斷、藥物和藥物的需求，以滿足泌尿系統疾病相關不斷成長的醫療需求，為醫療進步創造機會。干預措施。

缺乏合格的醫療專業人員

泌尿道疾病是非常規治療方法，需要專門的知識和專業知識來進行正確的管理和監測。缺乏合格的專業人員，包括泌尿系統和接受過泌尿系統疾病特殊培訓的醫療保健提供者，會導致診斷延遲、治療不足和患者照護不佳。此外，短缺可能會導致現有醫療保健專業人員的工作量增加，導致倦怠和護理品質不佳，從而阻礙市場成長。

提高泌尿系統健康意識和各種治療方案的可用性

隨著人們對泌尿系統疾病及其潛在後果的了解越來越多，人們越來越重視預防措施和早期發現。這一趨勢推動了患者檢查、諮詢和積極就醫行為的激增，對泌尿系統護理的需求產生了積極影響。這不僅滿足了個人偏好，還促進了個人化治療計劃並提高了患者的整體滿意度和依從性。意識的提高和治療方案的綜合效應正在促進市場成長。

缺乏標準化通訊協定和指南

泌尿道疾病治療缺乏既定標準，導致治療程序、劑量和使用方法存在差異，引發了人們對安全性、有效性和可重複性的擔憂。這些矛盾為醫療專業人員帶來了不確定性，並不願意將泌尿道疾病納入日常臨床實務。由於缺乏標準化和安全保證，患者可能不願意考慮泌尿道疾病的治療。標準化通訊協定的開發和推廣對於克服這些障礙和增強市場信心至關重要。

COVID-19 的影響

加上封鎖和旅行限制，醫療保健系統和資源面臨前所未有的壓力，導致泌尿系統手術延遲，並減少了因非緊急情況就診的患者。許多醫療機構已將重點和資源轉向應對 COVID-19 病例激增，從而影響了泌尿系統護理的提供。此外，大流行的經濟影響影響了患者的優先事項，有些人出於財務考慮而選擇推遲選擇性泌尿系統治療，從而阻礙了市場成長。

在預測期內，阻塞性尿路疾病領域預計將是最大的。

阻塞性尿路疾病領域預計將出現良好的成長，因為阻塞性尿路疾病患者的尿流不暢，可能導致各種併發症，如腎臟損傷和感染疾病。Masu。泌尿系統疾病治療市場對解決阻塞性泌尿系統疾病的干涉措施（例如外科手術、導管插入術和藥物治療）的需求可能會增加。此外，專注於解決阻塞性泌尿道疾病根本原因的研發可能會激增，包括開發標靶治療以推動市場成長。

尿液檢查領域預計在預測期內複合年成長率最高

尿液檢查領域預計在預測期內複合年成長率最高。這是因為，尿液樣本的分析可以讓醫療專業人員檢測到各種異常情況，例如感染疾病、腎臟疾病、代謝紊亂等，這些異常情況可能會影響泌尿系統疾病的治療過程。準確的尿液檢查結果有助於診斷泌尿系統疾病的根本原因，並制定個人化且有效的治療計畫。此外，尿液檢查有助於監測和評估治療效果，並允許根據患者反應進行調整，從而促進市場成長。

佔比最大的地區：

由於腎結石、前列腺肥大和尿失禁等泌尿系統疾病的高發生率，推動了對治療方案的需求，預計亞太地區在預測期內將佔據最大的市場佔有率。此外，微創手術、機器人輔助手術和先進的影像技術正在改變泌尿系統醫學，提供準確有效的治療和更快的恢復時間，推動該地區的市場成長。

複合年成長率最高的地區：

預計北美在預測期內的複合年成長率最高。這是因為腎結石、尿道感染(UTI) 和前列腺癌等疾病在北美變得越來越常見。這是由於人口老化、久坐的生活方式和肥胖率上升等因素所造成的。此外，泌尿系統領域近年來取得了重大進展，包括微創手術、機器人手術和個人化醫療方法的發展。這些進步正在改善患者的治療效果並縮短復原時間，從而推動市場成長。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球尿路疾病治療市場：依類型

  • 阻塞性泌尿道疾病
  • 功能性泌尿道疾病
  • 發炎泌尿道疾病
  • 先天性泌尿系統疾病
  • 泌尿系統癌症

第6章全球泌尿道疾病治療市場：依治療類型

  • 藥物治療
    • 抗生素
    • 止痛藥
    • α阻斷劑或α還原酶抑制劑
    • 荷爾蒙療法
  • 外科手術
    • 膀胱鏡
    • 碎石術
    • 輸尿管鏡
    • 支架置入
  • 生活方式改變

第7章全球泌尿道疾病治療市場：依診斷分類

  • 尿液檢查
  • 驗血
  • 影像檢查

第8章全球泌尿道疾病治療市場：依最終用戶分類

  • 醫院和診所
  • 門診手術中心
  • 其他

第9章全球泌尿道疾病治療市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • Abbott
  • Novartis AG
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Eli Lilly and Company
  • Ionis Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Merck & Co. Inc.
  • GlaxoSmithKline
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Antares Pharma
  • Allergan
  • AstraZeneca
  • Cook Medical
  • Sanofi
  • Olympus Corporation
  • Teleflex Incorporated
  • Argon Medical Devices, Inc
Product Code: SMRC25098

According to Stratistics MRC, the Global Uropathy Treatment Market is accounted for $4.4 billion in 2023 and is expected to reach $6.6 billion by 2030 growing at a CAGR of 6.0% during the forecast period. Uropathy refers to a broad range of conditions affecting the urinary tract, including the kidneys, ureters, bladder, and urethra. Treatment for uropathy depends on the specific underlying cause and severity of the condition. Innovation extends beyond procedures. Early diagnosis through advanced imaging techniques like 3D prostate MRI empowers timely intervention. Personalized medicine tailors treatment plans based on individual genetic and molecular profiles, paving the way for more effective and targeted therapies.

According to a study published in Advances in Urology, Kidney stone disease is an increasing urological disorder of human health which is affecting about 15% of the world population and it affects all age groups but occurs more frequently in men than in women within the age of 20-49 years.

Market Dynamics:

Driver:

Rising incidence of urological conditions

As the prevalence of disorders such as urinary tract infections, kidney stones, and prostate issues continues to rise, there is a heightened demand for effective and innovative treatments. This surge in patient numbers not only underscores the urgent need for advanced therapeutic solutions but also propels research and development efforts within the Uropathy Treatment sector. Thus the increased focus on urological health, fuelled by the rise in awareness and education, further amplifies the market's expansion, creating opportunities for advancements in diagnostics, pharmaceuticals, and medical interventions to cater to the escalating healthcare needs associated with urological conditions.

Restraint:

Shortage of qualified healthcare professionals

Uropathy, as an unconventional treatment, requires specialized knowledge and expertise for proper administration and monitoring. The scarcity of qualified professionals including urologists and healthcare providers with specific training in uropathy, results in delayed diagnosis, inadequate treatment, and compromised patient care. Moreover, the shortage contributes to increased workloads for existing healthcare professionals, potentially leading to burnout and decreased quality of care impeding the market growth.

Opportunity:

Increased awareness of urological health and the availability of various treatment options

As individuals become more informed about urological disorders and their potential consequences, there is a growing emphasis on preventive measures and early detection. This trend has driven a surge in patient screenings, consultations, and proactive healthcare seeking behaviours, positively influencing the demand for uropathy treatments. This not only caters to individual preferences but also promotes personalized treatment plans, enhancing overall patient satisfaction and compliance. The combined effect of heightened awareness and treatment options contributes to the growth of the market

Threat:

Lack of standardized protocols and guidelines

The lack of established norms for uropathy treatments leads to variability in procedures, dosages, and application methods, raising concerns about safety, efficacy, and reproducibility. This inconsistency creates uncertainty among healthcare professionals, making them hesitant to integrate uropathy into routine clinical practices. Patients may be hesitant to explore uropathy treatments due to the perceived lack of standardization and assurance of safety. Developing and promoting standardized protocols are essential for overcoming these obstacles and fostering confidence in the market.

Covid-19 Impact

The unprecedented strain on healthcare systems and resources, coupled with lockdowns and travel restrictions, has led to delays in urological procedures and reduced patient visits for non-emergent conditions. Many healthcare facilities have diverted their focus and resources toward managing the surge in COVID-19 cases, affecting the delivery of uropathy treatments. Moreover, the economic repercussions of the pandemic have influenced patient priorities, with some individuals opting to postpone elective urological treatments due to financial uncertainties hampering the market growth.

The obstructive uropathy segment is expected to be the largest during the forecast period

The obstructive uropathy segment is estimated to have a lucrative growth, as patients with obstructive uropathy may experience impaired urinary flow, leading to various complications such as kidney damage and infections. The market for uropathy treatment may see an increased demand for interventions addressing obstructive uropathy, including surgical procedures, catheterization, and pharmacological treatments. Additionally, the market may witness a surge in research and development efforts focused on addressing the underlying causes of obstructive uropathy, including the development of targeted therapies which encourage in the market growth.

The urinalysis segment is expected to have the highest CAGR during the forecast period

The urinalysis segment is anticipated to witness the highest CAGR growth during the forecast period, because the analysis of urine samples allows healthcare professionals to detect various abnormalities, such as infections, kidney diseases, and metabolic disorders, influencing the course of uropathy treatments. Precise urinalysis results aid in diagnosing the root cause of urological conditions, enabling personalized and effective treatment plans. Furthermore, urinalysis contributes to the monitoring and assessment of treatment efficacy, allowing adjustments based on patient responses boosting the markets growth.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the prevalence of urological conditions like kidney stones, prostate enlargement, and urinary incontinence increases in this region are fuelling demand for treatment options. Moreover minimally invasive surgeries, robotic-assisted procedures, and advanced imaging technologies are transforming urological care, offering precise and effective treatments with faster recovery times are driving the growth of the market in this region.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to Conditions like kidney stones, urinary tract infections (UTIs), and prostate cancer are becoming increasingly common in North America. This is due to factors like aging population, sedentary lifestyles, and rising obesity rates. Moreover, the field of urology has seen significant advancements in recent years, with the development of minimally invasive procedures, robotic surgery, and personalized medicine approaches. These advancements are leading to improved patient outcomes and shorter recovery times thus encouraging the growth of the market.

Key players in the market

Some of the key players in the Uropathy Treatment Market include Abbott, Novartis AG, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Genentech, Inc., Eli Lilly and Company, Ionis Pharmaceuticals, Inc., Pfizer, Inc., Merck & Co. Inc., GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., Bayer AG, Antares Pharma, Allergan, AstraZeneca, Cook Medical, Sanofi, Olympus Corporation, Teleflex Incorporated and Argon Medical Devices, Inc

Key Developments:

In January 2024, Abbott announced the first global procedures have been conducted using the company's new Volt™ Pulsed Field Ablation (PFA) System to treat patients battling common abnormal heart rhythms such as atrial fibrillation (AFib).

In January 2024, Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis. FDA approval of the company's second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond

In October 2023, Novartis confirms unconstrained supply for Pluvicto® and continues to significantly expand the number of treatment centers. Novartis is committed to providing a consistent, reliable supply of Pluvicto and making this important medicine readily available to patients.

Types Covered:

  • Obstructive Uropathy
  • Functional Uropathy
  • Inflammatory Uropathy
  • Congenital Uropathy
  • Urological Cancers

Treatment Types Covered:

  • Drug Therapy
  • Surgery Procedures
  • Lifestyle Modification

Diagnosis Covered:

  • Urinalysis
  • Blood Tests
  • Imaging Tests

End Users Covered:

  • Hospitals & Clinics
  • Ambulatory Surgical Centre
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Uropathy Treatment Market, By Type

  • 5.1 Introduction
  • 5.2 Obstructive Uropathy
  • 5.3 Functional Uropathy
  • 5.4 Inflammatory Uropathy
  • 5.5 Congenital Uropathy
  • 5.6 Urological Cancers

6 Global Uropathy Treatment Market, By Treatment Type

  • 6.1 Introduction
  • 6.2 Drug Therapy
    • 6.2.1 Antibiotics
    • 6.2.2 Pain Relievers
    • 6.2.3 Alpha-Blockers or Alpha-Reductase Inhibitors
    • 6.3.4 Hormone Therapy
  • 6.3 Surgery Procedures
    • 6.3.1 Cystoscopy
    • 6.3.2 Lithotripsy
    • 6.3.3 Ureteroscopy
    • 6.3.4 Stenting
  • 6.4 Lifestyle Modification

7 Global Uropathy Treatment Market, By Diagnosis

  • 7.1 Introduction
  • 7.2 Urinalysis
  • 7.3 Blood Tests
  • 7.4 Imaging Tests

8 Global Uropathy Treatment Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Ambulatory Surgical Centre
  • 8.4 Other End Users

9 Global Uropathy Treatment Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Abbott
  • 11.2 Novartis AG
  • 11.3 Bristol-Myers Squibb Co.
  • 11.4 F. Hoffmann-La Roche Ltd.
  • 11.5 Genentech, Inc.
  • 11.6 Eli Lilly and Company
  • 11.7 Ionis Pharmaceuticals, Inc.
  • 11.8 Pfizer, Inc.
  • 11.9 Merck & Co. Inc.
  • 11.10 GlaxoSmithKline
  • 11.11 Teva Pharmaceutical Industries Ltd.
  • 11.12 Bayer AG
  • 11.13 Antares Pharma
  • 11.14 Allergan
  • 11.15 AstraZeneca
  • 11.16 Cook Medical
  • 11.17 Sanofi
  • 11.18 Olympus Corporation
  • 11.19 Teleflex Incorporated
  • 11.20 Argon Medical Devices, Inc

List of Tables

  • Table 1 Global Uropathy Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Uropathy Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Uropathy Treatment Market Outlook, By Obstructive Uropathy (2021-2030) ($MN)
  • Table 4 Global Uropathy Treatment Market Outlook, By Functional Uropathy (2021-2030) ($MN)
  • Table 5 Global Uropathy Treatment Market Outlook, By Inflammatory Uropathy (2021-2030) ($MN)
  • Table 6 Global Uropathy Treatment Market Outlook, By Congenital Uropathy (2021-2030) ($MN)
  • Table 7 Global Uropathy Treatment Market Outlook, By Urological Cancers (2021-2030) ($MN)
  • Table 8 Global Uropathy Treatment Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 9 Global Uropathy Treatment Market Outlook, By Drug Therapy (2021-2030) ($MN)
  • Table 10 Global Uropathy Treatment Market Outlook, By Antibiotics (2021-2030) ($MN)
  • Table 11 Global Uropathy Treatment Market Outlook, By Pain Relievers (2021-2030) ($MN)
  • Table 12 Global Uropathy Treatment Market Outlook, By Alpha-Blockers or Alpha-Reductase Inhibitors (2021-2030) ($MN)
  • Table 13 Global Uropathy Treatment Market Outlook, By Hormone Therapy (2021-2030) ($MN)
  • Table 14 Global Uropathy Treatment Market Outlook, By Surgery Procedures (2021-2030) ($MN)
  • Table 15 Global Uropathy Treatment Market Outlook, By Cystoscopy (2021-2030) ($MN)
  • Table 16 Global Uropathy Treatment Market Outlook, By Lithotripsy (2021-2030) ($MN)
  • Table 17 Global Uropathy Treatment Market Outlook, By Ureteroscopy (2021-2030) ($MN)
  • Table 18 Global Uropathy Treatment Market Outlook, By Stenting (2021-2030) ($MN)
  • Table 19 Global Uropathy Treatment Market Outlook, By Lifestyle Modification (2021-2030) ($MN)
  • Table 20 Global Uropathy Treatment Market Outlook, By Diagnosis (2021-2030) ($MN)
  • Table 21 Global Uropathy Treatment Market Outlook, By Urinalysis (2021-2030) ($MN)
  • Table 22 Global Uropathy Treatment Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 23 Global Uropathy Treatment Market Outlook, By Imaging Tests (2021-2030) ($MN)
  • Table 24 Global Uropathy Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 25 Global Uropathy Treatment Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 26 Global Uropathy Treatment Market Outlook, By Ambulatory Surgical Centre (2021-2030) ($MN)
  • Table 27 Global Uropathy Treatment Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.